<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="rapid-communication" xml:lang="EN"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Med Chem Lett</journal-id><journal-id journal-id-type="iso-abbrev">ACS Med Chem Lett</journal-id><journal-id journal-id-type="publisher-id">ml</journal-id><journal-id journal-id-type="coden">amclct</journal-id><journal-title-group><journal-title>ACS Medicinal Chemistry Letters</journal-title></journal-title-group><issn pub-type="epub">1948-5875</issn><publisher><publisher-name>American Chemical
Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6746079</article-id><article-id pub-id-type="pmid">31531195</article-id><article-id pub-id-type="doi">10.1021/acsmedchemlett.9b00082</article-id><article-categories><subj-group><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Development of Pyridine-based Inhibitors for the Human
Vaccinia-related Kinases 1 and 2</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Serafim</surname><given-names>Ricardo
A. M.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="notes3" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>de Souza Gama</surname><given-names>Fernando H.</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="notes3" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Dutra</surname><given-names>Luiz A.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="notes3" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>dos Reis</surname><given-names>Caio V.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Vasconcelos</surname><given-names>Stanley N. S.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>da Silva Santiago</surname><given-names>Andr&#x000e9;</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Takarada</surname><given-names>J&#x000e9;ssica
E.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Di Pillo</surname><given-names>F&#x000fa;lvia</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Azevedo</surname><given-names>Hatylas</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath10"><name><surname>Mascarello</surname><given-names>Alessandra</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath11"><name><surname>Elkins</surname><given-names>Jonathan M.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath12"><name><surname>Massirer</surname><given-names>Katlin B.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath13"><name><surname>Gileadi</surname><given-names>Opher</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath14"><name><surname>Guimar&#x000e3;es</surname><given-names>Cristiano R. W.</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath15"><name><surname>Cou&#x000f1;ago</surname><given-names>Rafael M.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Centro
de Qu&#x000ed;mica Medicinal (CQMED), Centro de Biologia Molecular
e Engenharia Gen&#x000e9;tica (CBMEG), <institution>Universidade
Estadual de Campinas (UNICAMP)</institution>, Campinas, SP 13083-875, <country>Brazil</country></aff><aff id="aff2"><label>&#x02021;</label>Structural
Genomics Consortium, Departamento de Gen&#x000e9;tica e Evolu&#x000e7;&#x000e3;o,
Instituto de Biologia, <institution>UNICAMP</institution>, Campinas, SP 13083-886, <country>Brazil</country></aff><aff id="aff3"><label>&#x000a7;</label><institution>Ach&#x000e9;
Laborat&#x000f3;rios Farmac&#x000ea;uticos S.A.</institution>, Guarulhos, SP, <country>Brazil</country></aff><aff id="aff4"><label>&#x02225;</label>PhD
Program in Genetics and Molecular Biology (PGBM), <institution>UNICAMP</institution>, Campinas, SP 13083-886, <country>Brazil</country></aff><aff id="aff5"><label>&#x022a5;</label>Structural
Genomics Consortium, Nuffield Department of Medicine, <institution>University of Oxford</institution>, Oxford OX3 7DQ, <country>U.K.</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>E-mail: <email>rafael.counago@unicamp.br</email>.</corresp><corresp id="cor2"><label>*</label>E-mail: <email>cristiano.guimaraes@ache.com.br</email>.</corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>08</month><year>2019</year></pub-date><pub-date pub-type="collection"><day>12</day><month>09</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>08</month><year>2019</year></pub-date><volume>10</volume><issue>9</issue><fpage>1266</fpage><lpage>1271</lpage><history><date date-type="received"><day>01</day><month>03</month><year>2019</year></date><date date-type="accepted"><day>19</day><month>08</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 American Chemical Society</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>American Chemical Society</copyright-holder><license><license-p>This is an open access article published under a Creative Commons Attribution (CC-BY) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html">License</ext-link>, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml9b00082_0005" id="ab-tgr1"/></p><p>Vaccinia-related
kinases 1 and 2 (VRK1 and VRK2) are human Ser/Thr
protein kinases associated with increased cell division and neurological
disorders. Nevertheless, the cellular functions of these proteins
are not fully understood. Despite their therapeutic potential, there
are no potent and specific inhibitors available for VRK1 or VRK2.
We report here the discovery and elaboration of an aminopyridine scaffold
as a basis for VRK1 and VRK2 inhibitors. The most potent compound
for VRK1 (<bold>26</bold>) displayed an IC<sub>50</sub> value of 150
nM and was fairly selective in a panel of 48 human kinases (selectivity
score S(50%) of 0.04). Differences in compound binding mode and substituent
preferences between the two VRKs were identified by the structure&#x02212;activity
relationship combined with the crystallographic analysis of key compounds.
We expect our results to serve as a starting point for the design
of more specific and potent inhibitors against each of the two VRKs.</p></abstract><kwd-group><kwd>Vaccinia-related kinases</kwd><kwd>pyridine</kwd><kwd>difluorophenol</kwd><kwd>kinase inhibitors</kwd><kwd>structure-based compound development</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ml9b00082</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ml9b00082</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p>The human genome encodes three
vaccinia-related kinases (VRK1, VRK2, and VRK3).<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> VRK3 has a degraded ATP-binding site and is thought to
be a pseudokinase,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> while VRK1 and VRK2
feature active kinase domains and have been associated with various
cellular processes, including cell replication, chromatin remodeling,
and response to DNA damage.<sup><xref ref-type="bibr" rid="ref3">3</xref>&#x02212;<xref ref-type="bibr" rid="ref5">5</xref></sup> VRK2 has two isoforms that share
identical kinase domains but locate to distinct cellular compartments:
endoplasmic reticulum (VRK2A) and cytoplasm and nucleus (VRK2B).<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref6">6</xref></sup> VRK1 can be found in both nucleus and cytoplasm.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Genetic studies have associated VRK1 and VRK2 with a number
of human diseases and conditions. VRK2 is associated with neurological
disorders, such as schizophrenia, multiple sclerosis, major depressive
disorder, and epilepsy.<sup><xref ref-type="bibr" rid="ref7">7</xref>&#x02212;<xref ref-type="bibr" rid="ref11">11</xref></sup> VRK1 overexpression is associated with increased cell division and
poor prognosis in a number of cancers.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref></sup> Despite these
advances, our understanding of the cellular roles of human VRKs and
their therapeutic potential is limited. Currently, there are no potent
and specific small molecule inhibitors of the VRKs.</p><p>Previously,
our analysis of the Published Kinase Inhibitor Set
(PKIS)<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> revealed that VRK1 shared a similar
activity profile to a small number of kinases, including members of
the kinase family Ste20, such as MINK1 and TNIK.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> The Ste20 kinase family also includes MAP4K4, whose phosphate-binding
loop (P-loop, also referred to as glycine-rich loop) can adopt an
unusual conformation in which this conserved structural motif folds
over the ligand. It has been suggested that this folded P-loop conformation
might be targeted to obtain potent and selective kinase inhibitors.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Cocrystal structures of VRK1 and VRK2 bound
to the p90 RSK (ribosomal S6 kinase) inhibitor <bold>BI-D1870</bold> (<bold>1</bold>, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A) revealed that both kinases can also adopt the folded P-loop
conformation, further suggesting that MAP4K4 and these two VRKs have
similar topography and structural features in their ATP-binding sites.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup><bold>BI-D1870</bold> displays a highly developed
pteridine scaffold, and recent selectivity data revealed this compound
to be quite promiscuous.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> These observations
motivated us to search for MAP4K4 ligands known to induce a folded
P-loop conformation, and that could be used as starting points to
develop potent and selective inhibitors against VRK1 and VRK2.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>(A) Chemical
structure of <bold>1</bold> (<bold>BI-D1870</bold>) and the MAP4K4
inhibitor <bold>2</bold>. (B) Synthetic route to
aminopyridine derivatives.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml9b00082_0001" id="gr1" position="float"/></fig><p>2-Aminopyridines are well-known kinase inhibitor scaffolds, and
such compounds (exemplified by <bold>2</bold>, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A) have been shown to promote a folded P-loop
conformation in MAP4K4.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> Additionally,
this scaffold is small and versatile, allowing the attachment of different
substituents on both sides of the aminopyridine core by a short synthetic
route. The cocrystal structures of VRK1 and VRK2 bound to <bold>1</bold> (<bold>BI-D1870</bold>) also revealed that the ligand difluorophenol
moiety promoted favorable polar interactions to structurally conserved
residues within the VRK ATP-binding site.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Thus, our design strategy to develop new small molecule inhibitors
for VRK1 and VRK2 was to generate hybrid ligands by fusing the aminopyridine
core with the difluorophenol group.</p><p>Synthesis of aminopyridine
derivatives was performed using a rapid
and efficient two-step Suzuki&#x02013;Miyaura coupling (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B) with yields ranging between
18% and 89%. Each step was performed by a microwave-assisted reaction
in 1 h. Details of the procedure are available in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supporting Information</ext-link>.</p><p>To test our hybridization
hypothesis, we prepared prototype compound <bold>5</bold>, bearing
difluorophenol moieties in both, the 3- and 5-positions
of the 2-aminopyridine core (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). We employed a thermal-shift assay (differential
scanning fluorimetry, DSF) to identify aminopyridine analogues that
could bind to the full-length VRK1 (residues Met1-Lys396, VRK1-FL)
and the kinase domain of VRK2 (residues Pro14-His335, VRK2-KD). DSF
is a robust method to estimate binding affinities and has been used
successfully to triage large compound libraries.<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> For these experiments, we considered positive
hits those compounds inducing changes in VRK1-FL and VRK2-KD melting
temperatures, &#x00394;<italic>T</italic><sub>m</sub>, larger than 2.0&#x02009;&#x000b0;C.
DSF analysis indicated that <bold>5</bold> induced thermal shifts
above this threshold for both VRK1 and VRK2 (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Figure S1</ext-link>).</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Structures and Values for DSF and
Enzyme Inhibition Assays for Key Compounds</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml9b00082_0004" id="GRAPHIC-d7e506-autogenerated" position="float"/><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Values from ref (<xref ref-type="bibr" rid="ref15">15</xref>).</p></fn><fn id="t1fn2"><label>b</label><p>Confidence interval.</p></fn><fn id="t1fn3"><label>c</label><p>Not determined.</p></fn></table-wrap-foot></table-wrap><p>Encouraged by these results, we prepared a first series of 2-aminopyridine
analogues to explore the relevance of the difluorophenol moiety to
the thermal stabilization of the two VRKs (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Table S1</ext-link>). For both proteins, simultaneously replacing the difluorophenol
moiety with phenol groups in R<sup>1</sup> and R<sup>2</sup> (<bold>6</bold>) resulted in a drop of the observed &#x00394;<italic>T</italic><sub>m</sub>, suggesting that increasing the phenol acidic character
or altering the electronic properties of the aromatic ring was important
for binding.<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></sup> VRK1-FL seemed to tolerate the
substitution of a difluorophenol by a phenol on either R<sup>1</sup> or R<sup>2</sup> position equally well, whereas maintaining a difluorophenol
group in R<sup>1</sup> proved to be more important for VRK2-KD binding
(<bold>8</bold> and <bold>7</bold>). Not unexpectedly, removal of
the HB (hydrogen bond) capacity in R<sup>2</sup>, while maintaining
the difluorophenol group in R<sup>1</sup>, still resulted in a &#x00394;<italic>T</italic><sub>m</sub> drop for both VRKs (<bold>9</bold>). We attempted
to improve compound binding by replacing the difluorophenol in R<sup>1</sup> with a variety of groups of distinct sizes, polarities, and
electronic proprieties, but none of these changes resulted in an improved
&#x00394;<italic>T</italic><sub>m</sub> over the difluorophenol moiety.</p><p>We next explored the ability of various phenyl derivatives in R<sup>2</sup> to optimize the compound binding profile, while maintaining
a difluorophenol group in R<sup>1</sup> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Table S1</ext-link>). Our results confirmed that polar groups in R<sup>2</sup> are important for binding the VRKs and indicated that, overall,
these groups were better tolerated in the meta position (<bold>10</bold> vs <bold>11</bold>; <bold>12</bold> vs <bold>13</bold>; <bold>14</bold> vs <bold>15</bold> and <bold>16</bold>), although the addition of
a carboxylic acid group in this position was detrimental to binding
(<bold>17</bold>). For VRK2-KD, the best compound had a <italic>para</italic>-sulfonamide group on the R<sup>2</sup> phenyl ring (<bold>18</bold>), although a benzothiazole fused ring (<bold>19</bold>) was also
tolerated in this position. VRK1-FL tolerated both of these groups
in R<sup>2</sup> equally well. Nevertheless, for VRK1, we could not
find a R<sup>2</sup> substituent that increased <italic>T</italic><sub>m</sub>-shifts compared to the difluorophenol moiety (<bold>5</bold>). For VRK2-KD, further attempts to modify the difluorophenol
in R<sup>1</sup> while maintaining the sulfonamide group in R<sup>2</sup> were unsuccessful (<bold>20</bold>, <bold>21</bold>, and <bold>22</bold>).</p><p>Although robust, DSF provides only limited information
on compound
binding to a target protein. We then developed an enzyme inhibition
assay (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Figure S2</ext-link>) and determined
the potency (IC<sub>50</sub>) of key compounds against VRK1-FL (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Table S2</ext-link>). In these assays, our prototype compound <bold>5</bold> had an IC<sub>50</sub> value of 260 nM, &#x0223c;8-fold higher than
the one observed for <bold>1</bold> (<bold>BI-D1870</bold>, 33 nM).
Estimated IC<sub>50</sub> values were in good agreement with our DSF
results. For example, <bold>19</bold>, with a &#x00394;<italic>T</italic><sub>m</sub> of 2.2 &#x000b0;C, had an IC<sub>50</sub> of 674 nM against
VRK1-FL (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Figure S3</ext-link>). More
importantly, our enzymatic assays confirmed these compounds as inhibitors
of VRK1.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Biochemical, biophysical, and selectivity profile characterization
of key compounds. (A) IC<sub>50</sub> determination curves for <bold>1</bold>, <bold>5</bold>, and <bold>26</bold> against VRK1-FL. Individual
data points are the mean &#x000b1; SD of three technical replicates.
Estimated IC<sub>50</sub> values are shown in parentheses. (B,C) ITC
measurements for top compounds in the DSF assay for VRK2-KD (<bold>18</bold>) and VRK1-FL (<bold>26</bold>). Values for binding energies
are shown in kJ/mol. (D) Selectivity profile of <bold>1</bold> (<bold>BI-D1870</bold>), <bold>5</bold>, and <bold>26</bold> against a representative
panel of 48 human kinases at 1 &#x003bc;M concentration. Colors denote
% residual kinase activity: green, residual activity &#x0003e;80%; yellow,
residual activity &#x02265;40% and &#x02264;80%; red, residual activity
&#x0003c;40%. Residual activity values are shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Table S5</ext-link>. Numbers in parentheses report the
selectivity score S(50%) for each compound. S(50%) was obtained by
dividing the number of protein kinases having % residual activity
&#x02264;50%, by the total number of tested protein kinases. Distribution
of selected kinases across the human kinome is shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Figure S7</ext-link>. The VRKs were not part
of the panel.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml9b00082_0002" id="gr2" position="float"/></fig><p>Unfortunately, we did not succeed
in developing a similar enzymatic
assay for VRK2. Thus, we employed isothermal titration calorimetry
(ITC) to estimate binding potency (<italic>K</italic><sub>D</sub>)
of selected compounds to VRK2-KD, including <bold>18</bold>, our top
compound from the DSF assay (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Figure S4</ext-link>). Our ITC data confirmed binding of these compounds to VRK2-KD and
revealed these interactions to be mostly enthalpy-driven (|&#x00394;<italic>H</italic>| &#x0003e; |<italic>T</italic>&#x00394;<italic>S</italic>|) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Table S3</ext-link>). As expected, <bold>18</bold> had the strongest binding to VRK2 (<italic>K</italic><sub>D</sub> &#x02248; 400 nM). At the moment, we cannot offer an explanation
for the discrepancy between ITC and DSF results for <bold>13</bold> and <bold>19</bold>.</p><p>To better understand the molecular basis
for ligand binding, we
obtained cocrystals of VRK1-KD (residues Arg3-Glu364) bound to <bold>5</bold> and VRK2-KD bound to <bold>18</bold> (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>). Both structures were solved by molecular
replacement (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Table S4</ext-link>). Ligand-bound
VRK1-KD and VRK2-KD adopted an active conformation, in which conserved
residues from structurally conserved elements of the kinase domain
(Glu83 and Lys71 within &#x003b1;C-helix and the ATP-binding site, respectively,
VRK1 numbering) are brought into close proximity, and the side chain
of Asp197 (VRK1 numbering) from the conserved DFG motif (DYG in the
VRKs) points toward the ATP-binding site (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Figure S5A,B</ext-link>).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Cocrystal structures revealed distinct compound binding
modes.
(A,B) VRK1-KD bound to <bold>5</bold>. The compound adopts two different
binding modes with different VRK1 molecules in the crystal. (C) VRK2-KD
bound to <bold>18</bold>. Black dashed lines represent potential hydrogen
bonds. Bottom panels show electron density maps (2<italic>F</italic><sub><italic>o</italic></sub> &#x02013; <italic>F</italic><sub><italic>c</italic></sub>) contoured at 1.0&#x003c3;.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml9b00082_0003" id="gr3" position="float"/></fig><p>As expected, <bold>5</bold> and <bold>18</bold> were found in the
ATP-binding sites of VRK1 and VRK2, respectively (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A,B). The binding pose for <bold>18</bold> showed the 2-amino moiety pointed toward the back of VRK2
ATP-binding site. The 2-amino group and the pyridine N atom of <bold>18</bold> established one hydrogen bond each to the carbonyl and
amide groups of VRK2 hinge residues Glu122 and Leu124, respectively.
In VRK1-KD crystals, the ligand could be observed in three out of
the four protein molecules in the asymmetric unit and, surprisingly,
was found in two different poses. The first of these was equivalent
to the one observed for <bold>18</bold> bound to VRK2-KD. In the second
binding mode, the 2-amino group of <bold>5</bold> pointed toward the
solvent and, together with the pyridine nitrogen atom, facilitated
HBs with main chain atoms from VRK1-KD hinge residue Phe134.</p><p>The cocrystal structures helped us to rationalize the relevance
of the difluorophenol moiety for binding. Regardless of compound binding
pose, this group facilitated a HB network with polar side chains from
structurally conserved residues within the kinase domain of VRK1 (Lys71
and Glu83) and VRK2 (Lys61 and Glu73). The difluorophenol group participating
in these contacts displayed distinct dihedral angles to the 2-amino
core depending on its attachment position: &#x0223c;45&#x000b0; in R<sup>1</sup> and &#x0223c;9&#x000b0; in R<sup>2</sup>. In VRK1, these different
orientations of the difluorophenol group were accommodated by a corresponding
movement of the side chain from residue Met131, which occupies the
gatekeeper position in this protein. Consequently, the difluorophenol
group fitted tightly between the &#x003b1;C-helix and the gatekeeper
residue in both poses. These observations might explain why we could
not find substituents that improved binding over the difluorophenol
group.</p><p>The VRK2-KD cocrystal structure also revealed that the <bold>18</bold> sulfonamide group pointed away from the protein ATP-binding
site
and was mostly solvent-exposed. A similar observation was made for
the difluorophenol group in <bold>5</bold> that did not interact with
VRK1-KD &#x003b1;C-helix (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Figure S5D&#x02013;F</ext-link>). Our DSF results also indicated that placement of polar groups
in the meta-position resulted in slight increases of &#x00394;<italic>T</italic><sub>m</sub>, especially for VRK2-KD (<bold>10</bold> vs <bold>11</bold>, for example). At this position, polar groups from the
ligand might be able to engage polar groups from VRK2-KD P-loop.</p><p>Regardless of the ligand binding pose, the P-loop of VRK1 was found
to be folded over <bold>5</bold>. This conformation was likely stabilized
by hydrophobic interactions observed between P-loop residue Phe48
and <bold>5</bold>&#x02019;s three-ring system. By contrast, VRK2 P-loop
did not fold over <bold>18</bold>. In our VRK2 cocrystal, the P-loop
was found rotated toward the protein &#x003b1;C-helix by &#x0223c;6 &#x000c5;
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Figure S5C</ext-link>). Consequently,
equivalent aromatic residues within the P-loop of VRK1 (Phe48) and
VRK2 (Phe40) occupied different positions in each of the proteins&#x02019;
ATP-binding site.</p><p>The two binding modes observed for <bold>5</bold> in VRK1 suggested
that the 2-amino moiety had no binding preference for either of the
hinge carbonyl groups it can interact with (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A,B). This led us to hypothesize that these
two interactions were either equally productive or equally weak in
the binding process. To address these hypotheses, we synthesized the
following analogues: (i) <bold>23</bold>, with two amino groups that
could interact with both hinge carbonyl groups simultaneously; (ii) <bold>24</bold>, with a 2-amino and a space-filling 6-methyl group; (iii) <bold>25</bold>, with the 2-amino group removed; and (iv) <bold>26</bold>, with the 2-amino group substituted by a 2-methyl group (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Table S1</ext-link>).</p><p>DSF assays revealed that none
of these new analogs had improved
&#x00394;<italic>T</italic><sub>m</sub> values for VRK2-KD (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Table S1</ext-link>). These results suggested that the
HB between the hinge carbonyl group and the 2-aminopyridine core is
a productive interaction for VRK2. Likewise, for VRK1-FL, compounds <bold>23</bold>, <bold>24</bold>, and <bold>25</bold> did not improve &#x00394;<italic>T</italic><sub>m</sub> values over those observed for <bold>5</bold>. Poor results observed for <bold>23</bold> and <bold>24</bold> might
be explained by clashes between one of the two substituents in these
compounds (at the 2- or 6-position in the pyridine core) and main
chain atoms from residues within the kinase hinge region.</p><p>By
contrast, <bold>26</bold> and <bold>5</bold> were equipotent
in the DSF assay, supporting the hypothesis that the 2-amino moiety
contributed little to the binding of <bold>5</bold> to VRK1. Thus,
both our DSF results and crystal structures suggested that VRK1, but
not VRK2, was capable of binding equally well to the 2-aminopyridine
core in two different conformations.</p><p>Further, the increase in
&#x00394;<italic>T</italic><sub>m</sub> observed
for <bold>26</bold> (2-methylpyridine core) over <bold>25</bold> (pyridine
core) for VRK1 might arise from favorable electron-donating properties
or conformational effects conferred to the pyridine ring system by
the presence of an adjacent methyl group.<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> Alternatively, the lack of a substituent group in the 2-position
may incur a free energy penalty associated with <bold>25</bold>&#x02019;s
inability to fill in a cavity in the protein binding pocket.</p><p>Enzyme inhibition assays further confirmed <bold>26</bold> as a
VRK1 inhibitor with an IC<sub>50</sub> value of &#x0223c;150 nM, a
&#x0223c;2-fold increase in potency over prototype compound <bold>5</bold> (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A, <xref rid="tbl1" ref-type="other">Table<xref rid="tbl1" ref-type="other">1</xref></xref>). ITC experiments
determined that binding of <bold>26</bold> to VRK1-FL was enthalpy-driven
and had a <italic>K</italic><sub>D</sub> of 190 nM (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>C, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Table S3</ext-link>).</p><p>The 2-amino-pyridine moiety is a common feature
of many kinase
inhibitors and often plays a role in binding to the kinase hinge region
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Figure S6</ext-link>).<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> We were surprised that changes in hinge-binding groups
within the pyridine core had such marked impact on compound binding
to each of the VRKs, as these proteins have highly similar ATP-binding
sites. Motivated by these findings, we assessed the activity of <bold>1</bold>, <bold>5</bold>, and <bold>26</bold> against a representative
panel of 48 human kinases at 1 &#x003bc;M concentration (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>D, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Figure S7</ext-link>). Our results showed that introduction of the methyl
group in the pyridine scaffold markedly improved selectivity of <bold>26</bold> over prototype <bold>5</bold>; S(50%) scores of 0.04 and
0.25, respectively. Our selectivity data also confirmed previous reports
that <bold>1</bold> (<bold>BI-D1870</bold>) is fairly promiscuous;<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> S(50%) score of 0.19.</p><p>To ascertain that <bold>18</bold> and <bold>26</bold> represented
tractable molecules for development into chemical probes suitable
for biological studies, we performed cell viability assays based on
the metabolic conversion of a tetrazolium dye (MTT, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supporting Information</ext-link>) to its insoluble formazan
by human (HeLa) cells. Our results indicated that there was no noticeable
effect on cell viability after a 24-h treatment with 3.2 &#x003bc;M
of <bold>18</bold> and only a slight decrease with 3.2 &#x003bc;M of <bold>26</bold>; and &#x02265;60% of cells remained viable after the compound
concentration was raised to 12.5 &#x003bc;M of <bold>18</bold> and 25
&#x003bc;M of <bold>26</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">Supplementary Figure S8</ext-link>).</p><p>In conclusion, we report here the use of the pyridine
scaffold
for the development of inhibitors against VRK1 and VRK2. Our data
revealed <bold>26</bold> to be a selective (S(50%) 0.04) and potent
(IC<sub>50</sub> &#x02248; 150 nM) inhibitor of VRK1. Compound <bold>18</bold> binds to VRK2 in the mid-nM range (ITC <italic>K</italic><sub>D</sub> 400 nM). Further characterization of this compound is
likely to confirm <bold>18</bold> as an inhibitor of the VRK2 protein.
Both compounds are not overtly toxic to human cells and represent
promising starting points for developing more potent and selective
inhibitors for VRK1 and VRK2. Future optimization efforts will take
advantage of the scaffold&#x02019;s good synthetic accessibility.</p></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is
available free of charge on the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org">ACS Publications website</ext-link> at DOI: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.9b00082">10.1021/acsmedchemlett.9b00082</ext-link>.<list id="silist" list-type="simple"><list-item><p>Supplementary Tables S1&#x02013;S5,
Supplementary Figures
S1&#x02013;S8, Supplementary Methods, and Supplementary References
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00082/suppl_file/ml9b00082_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml9b00082_si_001.pdf"><caption><p>ml9b00082_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="accession-codes" id="notes5"><title>Accession Codes</title><p>The atomic coordinates
and crystallographic structures factors for VRK1-KD bound to <bold>5</bold> and for VRK2-KD bound to <bold>18</bold> have been deposited
in the Protein Data Bank (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.rcsb.org">www.rcsb.org</uri>) with accession codes 6BU6 and 6NCG, respectively.</p></notes><notes notes-type="" id="notes3"><title>Author Contributions</title><p><sup>#</sup> These authors contributed equally. R.A.M.S., F.H.S.G., S.N.S.V.,
H.A., A.M., and C.R.W.G. designed all molecules. R.A.M.S., F.H.S.G.,
and S.N.S.V. synthesized and characterized all molecules. C.V.R. and
R.M.C. designed and performed crystallization experiments, X-ray diffraction
data collection, and protein structure determination and analysis.
A.S.S. designed, performed, and analyzed ITC experiments for VRK2-KD.
J.E.T. designed, performed, and analyzed ITC experiments for VRK1-FL.
C.V.R., A.S.S., and L.A.D. designed, performed, and analyzed DSF experiments.
L.A.D. designed, performed, and analyzed enzymatic assays. F.D.P.
designed, performed, and analyzed cell assays. H.A., A.M., J.M.E., K.B.M., O.G., C.R.W.G.,
and R.M.C. coordinated the project. R.A.M.S. and R.M.C. wrote the
manuscript. All authors revised the manuscript. All authors have given
approval to the final version of the manuscript.</p></notes><notes notes-type="funding-statement" id="notes4"><p>This work was
supported by the Brazilian agencies FAPESP (Funda&#x000e7;&#x000e3;o
de Amparo &#x000e0; Pesquisa do Estado de S&#x000e3;o Paulo) (2013/50724-5
and 2014/5087-0), Embrapii (Empresa Brasileira de Pesquisa e Inova&#x000e7;&#x000e3;o
Industrial), and CNPq (Conselho Nacional de Desenvolvimento Cient&#x000ed;fico
e Tecnol&#x000f3;gico) (465651/2014-3 and 400906/2014-7). The SGC is
a registered charity (number 1097737) that receives funds from AbbVie,
Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation,
Eshelman Institute for Innovation, Genome Canada, Innovative Medicines
Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck
KGaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry
of Economic Development and Innovation, Pfizer, Takeda, and Wellcome
[106169/ZZ14/Z]. R.A.M.S., S.N.S.V. and F.D.P. received FAPESP fellowships
(2016/25320-6, 2018/09475-5 and 2018/03359-3 respectively). C.V.R.
and A.S.S. received CAPES (Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento
de Pessoal de N&#x000ed;vel Superior) postdoctoral fellowships (88887.146077/2017-00
and 88887.136342/2017-00, respectively).</p></notes><notes notes-type="COI-statement" id="notes6"><p>The authors
declare the following competing financial interest(s): The authors
F.H.S.G., H.A., A.M., C.R.W.G. are employed by Ach&#x000e9; Laborat&#x000f3;rios
Farmac&#x000ea;uticos. All other authors declare no competing financial
interest.</p></notes><ack><title>Acknowledgments</title><p>We thank the staff of the Proteomics
section of
the Life Sciences Core Facility (LaCTAD), part of the University of
Campinas (UNICAMP), for their contributions to ITC analysis. We thank
the staff at the Northeastern Collaborative Access Team beamlines
(GU56413 and GU54127), which are funded by the National Institute
of General Medical Sciences from the National Institutes of Health
(P41 GM103403). The Pilatus 6M detector on the 24-ID-C beamline is
funded by a NIH-ORIP HEI grant (S10 RR029205). This research used
resources of the Advanced Photon Source, a U.S. Department of Energy
(DOE) Office of Science User Facility operated for the DOE Office
of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.</p></ack><glossary id="dl1"><def-list><title>ABBREVIATIONS</title><def-item><term>VRK</term><def><p>Vaccinia-related
kinase</p></def></def-item><def-item><term>KD</term><def><p>kinase
domain</p></def></def-item><def-item><term>FL</term><def><p>full-length</p></def></def-item><def-item><term>HB</term><def><p>hydrogen bond</p></def></def-item><def-item><term>MTT</term><def><p>3-(4,5-dimetrylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Nichols</surname><given-names>R. J.</given-names></name>; <name><surname>Traktman</surname><given-names>P.</given-names></name>
<article-title>Characterization of
Three Paralogous Members of the
Mammalian Vaccinia Related Kinase Family</article-title>. <source>J.
Biol. Chem.</source>
<year>2004</year>, <volume>279</volume> (<issue>9</issue>), <fpage>7934</fpage><pub-id pub-id-type="doi">10.1074/jbc.M310813200</pub-id>.<pub-id pub-id-type="pmid">14645249</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Scheeff</surname><given-names>E. D.</given-names></name>; <name><surname>Eswaran</surname><given-names>J.</given-names></name>; <name><surname>Bunkoczi</surname><given-names>G.</given-names></name>; <name><surname>Knapp</surname><given-names>S.</given-names></name>; <name><surname>Manning</surname><given-names>G.</given-names></name>
<article-title>Structure
of the Pseudokinase VRK3 Reveals a Degraded Catalytic Site, a Highly
Conserved Kinase Fold, and a Putative Regulatory Binding Site</article-title>. <source>Structure</source>
<year>2009</year>, <volume>17</volume> (<issue>1</issue>), <fpage>128</fpage><pub-id pub-id-type="doi">10.1016/j.str.2008.10.018</pub-id>.<pub-id pub-id-type="pmid">19141289</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Kang</surname><given-names>T.-H.</given-names></name>; <name><surname>Park</surname><given-names>D.-Y.</given-names></name>; <name><surname>Choi</surname><given-names>Y. H.</given-names></name>; <name><surname>Kim</surname><given-names>K.-J.</given-names></name>; <name><surname>Yoon</surname><given-names>H. S.</given-names></name>; <name><surname>Kim</surname><given-names>K.-T.</given-names></name>
<article-title>Mitotic Histone H3 Phosphorylation
by Vaccinia-Related
Kinase 1 in Mammalian Cells</article-title>. <source>Mol. Cell. Biol.</source>
<year>2007</year>, <volume>27</volume> (<issue>24</issue>), <fpage>8533</fpage><pub-id pub-id-type="doi">10.1128/MCB.00018-07</pub-id>.<pub-id pub-id-type="pmid">17938195</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Molitor</surname><given-names>T. P.</given-names></name>; <name><surname>Traktman</surname><given-names>P.</given-names></name>
<article-title>Depletion of the Protein
Kinase VRK1 Disrupts Nuclear
Envelope Morphology and Leads to BAF Retention on Mitotic Chromosomes</article-title>. <source>Mol. Biol. Cell</source>
<year>2014</year>, <volume>25</volume> (<issue>6</issue>), <fpage>891</fpage><pub-id pub-id-type="doi">10.1091/mbc.e13-10-0603</pub-id>.<pub-id pub-id-type="pmid">24430874</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Monsalve</surname><given-names>D. M.</given-names></name>; <name><surname>Merced</surname><given-names>T.</given-names></name>; <name><surname>Fern&#x000e1;ndez</surname><given-names>I. F.</given-names></name>; <name><surname>Blanco</surname><given-names>S.</given-names></name>; <name><surname>V&#x000e1;zquez-Cedeira</surname><given-names>M.</given-names></name>; <name><surname>Lazo</surname><given-names>P. A.</given-names></name>
<article-title>Human VRK2Modulates Apoptosis by Interaction with Bcl-XL
and Regulation of BAX Gene Expression</article-title>. <source>Cell
Death Dis.</source>
<year>2013</year>, <volume>4</volume> (<issue>2</issue>), <elocation-id>e513</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2013.40</pub-id>.<pub-id pub-id-type="pmid">23449449</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Blanco</surname><given-names>S.</given-names></name>; <name><surname>Klimcakova</surname><given-names>L.</given-names></name>; <name><surname>Vega</surname><given-names>F. M.</given-names></name>; <name><surname>Lazo</surname><given-names>P. A.</given-names></name>
<article-title>The Subcellular
Localization of Vaccinia-Related Kinase-2 (VRK2) Isoforms Determines
Their Different Effect on P53 Stability in Tumour Cell Lines</article-title>. <source>FEBS J.</source>
<year>2006</year>, <volume>273</volume> (<issue>11</issue>), <fpage>2487</fpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2006.05256.x</pub-id>.<pub-id pub-id-type="pmid">16704422</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Li</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Zheng</surname><given-names>X. B.</given-names></name>; <name><surname>Ikeda</surname><given-names>M.</given-names></name>; <name><surname>Iwata</surname><given-names>N.</given-names></name>; <name><surname>Luo</surname><given-names>X. J.</given-names></name>; <name><surname>Chong</surname><given-names>S. A.</given-names></name>; <name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Rietschel</surname><given-names>M.</given-names></name>; <name><surname>Zhang</surname><given-names>F.</given-names></name>; et al. <article-title>Meta-Analysis and Brain
Imaging Data Support the Involvement
of VRK2 (Rs2312147) in Schizophrenia Susceptibility</article-title>. <source>Schizophr. Res.</source>
<year>2012</year>, <volume>142</volume> (<issue>1&#x02013;3</issue>), <fpage>200</fpage><pub-id pub-id-type="doi">10.1016/j.schres.2012.10.008</pub-id>.<pub-id pub-id-type="pmid">23102693</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Chang</surname><given-names>H.</given-names></name>; <name><surname>Zhang</surname><given-names>C.</given-names></name>; <name><surname>Xiao</surname><given-names>X.</given-names></name>; <name><surname>Pu</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Wu</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name>
<article-title>Further Evidence of VRK2 Rs2312147
Associated with
Schizophrenia</article-title>. <source>World J. Biol. Psychiatry</source>
<year>2016</year>, <volume>17</volume> (<issue>6</issue>), <fpage>457</fpage><pub-id pub-id-type="doi">10.1080/15622975.2016.1200746</pub-id>.<pub-id pub-id-type="pmid">27382989</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Azimi</surname><given-names>T.</given-names></name>; <name><surname>Ghafouri-Fard</surname><given-names>S.</given-names></name>; <name><surname>Davood Omrani</surname><given-names>M.</given-names></name>; <name><surname>Mazdeh</surname><given-names>M.</given-names></name>; <name><surname>Arsang-Jang</surname><given-names>S.</given-names></name>; <name><surname>Sayad</surname><given-names>A.</given-names></name>; <name><surname>Taheri</surname><given-names>M.</given-names></name>
<article-title>Vaccinia Related Kinase 2 (VRK2)
Expression in Neurological Disorders: Schizophrenia, Epilepsy and
Multiple Sclerosis</article-title>. <source>Mult. Scler. Relat. Disord.</source>
<year>2018</year>, <volume>19</volume>, <fpage>15</fpage><pub-id pub-id-type="doi">10.1016/j.msard.2017.10.017</pub-id>.<pub-id pub-id-type="pmid">29100046</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Li</surname><given-names>M.</given-names></name>; <name><surname>Yue</surname><given-names>W.</given-names></name>
<article-title>VRK2, a Candidate Gene
for Psychiatric and Neurological Disorders</article-title>. <source>Mol. Neuropsychiatry</source>
<year>2018</year>, <volume>4</volume> (<issue>3</issue>), <fpage>119</fpage><pub-id pub-id-type="doi">10.1159/000493941</pub-id>.<pub-id pub-id-type="pmid">30643786</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Jeong</surname><given-names>Y.-H.</given-names></name>; <name><surname>Choi</surname><given-names>J.-H.</given-names></name>; <name><surname>Lee</surname><given-names>D.</given-names></name>; <name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>Kim</surname><given-names>K.-T.</given-names></name>
<article-title>Vaccinia-Related
Kinase 2 Modulates Role of Dysbindin by Regulating Protein Stability</article-title>. <source>J. Neurochem.</source>
<year>2018</year>, <volume>147</volume> (<issue>5</issue>), <fpage>609</fpage><pub-id pub-id-type="doi">10.1111/jnc.14562</pub-id>.<pub-id pub-id-type="pmid">30062698</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Huang</surname><given-names>W.</given-names></name>; <name><surname>Cui</surname><given-names>X.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Shao</surname><given-names>M.</given-names></name>; <name><surname>Shao</surname><given-names>X.</given-names></name>; <name><surname>Shen</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>Q.</given-names></name>; <name><surname>Wu</surname><given-names>M.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Ni</surname><given-names>W.</given-names></name>; et al. <article-title>High VRK1
Expression Contributes to Cell Proliferation and Survival in Hepatocellular
Carcinoma</article-title>. <source>Pathol., Res. Pract.</source>
<year>2016</year>, <volume>212</volume> (<issue>3</issue>), <fpage>171</fpage><pub-id pub-id-type="doi">10.1016/j.prp.2015.11.015</pub-id>.<pub-id pub-id-type="pmid">26706601</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Ben</surname><given-names>Z.</given-names></name>; <name><surname>Gong</surname><given-names>L.</given-names></name>; <name><surname>Qiu</surname><given-names>Y.</given-names></name>
<article-title>High Expression
of VRK1 Is Related
to Poor Prognosis in Glioma</article-title>. <source>Pathol., Res. Pract.</source>
<year>2018</year>, <volume>214</volume> (<issue>1</issue>), <fpage>112</fpage><pub-id pub-id-type="doi">10.1016/j.prp.2017.10.014</pub-id>.<pub-id pub-id-type="pmid">29103766</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Elkins</surname><given-names>J. M.</given-names></name>; <name><surname>Fedele</surname><given-names>V.</given-names></name>; <name><surname>Szklarz</surname><given-names>M.</given-names></name>; <name><surname>Abdul Azeez</surname><given-names>K. R.</given-names></name>; <name><surname>Salah</surname><given-names>E.</given-names></name>; <name><surname>Mikolajczyk</surname><given-names>J.</given-names></name>; <name><surname>Romanov</surname><given-names>S.</given-names></name>; <name><surname>Sepetov</surname><given-names>N.</given-names></name>; <name><surname>Huang</surname><given-names>X. P.</given-names></name>; <name><surname>Roth</surname><given-names>B. L.</given-names></name>; et al. <article-title>Comprehensive Characterization
of the Published Kinase Inhibitor Set</article-title>. <source>Nat.
Biotechnol.</source>
<year>2016</year>, <volume>34</volume> (<issue>1</issue>), <fpage>95</fpage><pub-id pub-id-type="doi">10.1038/nbt.3374</pub-id>.<pub-id pub-id-type="pmid">26501955</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Cou&#x000f1;ago</surname><given-names>R. M.</given-names></name>; <name><surname>Allerston</surname><given-names>C. K.</given-names></name>; <name><surname>Savitsky</surname><given-names>P.</given-names></name>; <name><surname>Azevedo</surname><given-names>H.</given-names></name>; <name><surname>Godoi</surname><given-names>P. H.</given-names></name>; <name><surname>Wells</surname><given-names>C. I.</given-names></name>; <name><surname>Mascarello</surname><given-names>A.</given-names></name>; <name><surname>de Souza Gama</surname><given-names>F. H.</given-names></name>; <name><surname>Massirer</surname><given-names>K. B.</given-names></name>; <name><surname>Zuercher</surname><given-names>W. J.</given-names></name>; et al. <article-title>Structural Characterization
of Human Vaccinia-Related Kinases (VRK) Bound to Small-Molecule Inhibitors
Identifies Different P-Loop Conformations</article-title>. <source>Sci.
Rep.</source>
<year>2017</year>, <volume>7</volume> (<issue>1</issue>), <fpage>7501</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-07755-y</pub-id>.<pub-id pub-id-type="pmid">28790404</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Guimar&#x000e3;es</surname><given-names>C. R.
W.</given-names></name>; <name><surname>Rai</surname><given-names>B. K.</given-names></name>; <name><surname>Munchhof</surname><given-names>M. J.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Bhattacharya</surname><given-names>S. K.</given-names></name>; <name><surname>Buckbinder</surname><given-names>L.</given-names></name>
<article-title>Understanding the Impact of the P-Loop
Conformation on Kinase Selectivity</article-title>. <source>J. Chem.
Inf. Model.</source>
<year>2011</year>, <volume>51</volume> (<issue>6</issue>), <fpage>1199</fpage><pub-id pub-id-type="doi">10.1021/ci200153c</pub-id>.<pub-id pub-id-type="pmid">21568278</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Aronchik</surname><given-names>I.</given-names></name>; <name><surname>Appleton</surname><given-names>B. A.</given-names></name>; <name><surname>Basham</surname><given-names>S. E.</given-names></name>; <name><surname>Crawford</surname><given-names>K.</given-names></name>; <name><surname>Del Rosario</surname><given-names>M.</given-names></name>; <name><surname>Doyle</surname><given-names>L. V.</given-names></name>; <name><surname>Estacio</surname><given-names>W. F.</given-names></name>; <name><surname>Lan</surname><given-names>J.</given-names></name>; <name><surname>Lindvall</surname><given-names>M. K.</given-names></name>; <name><surname>Luu</surname><given-names>C. A.</given-names></name>; et al. <article-title>Novel Potent and Selective
Inhibitors of P90 Ribosomal
S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven
Cancers</article-title>. <source>Mol. Cancer Res.</source>
<year>2014</year>, <volume>12</volume> (<issue>5</issue>), <fpage>803</fpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-13-0595</pub-id>.<pub-id pub-id-type="pmid">24554780</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Ammirati</surname><given-names>M.</given-names></name>; <name><surname>Bagley</surname><given-names>S. W.</given-names></name>; <name><surname>Bhattacharya</surname><given-names>S. K.</given-names></name>; <name><surname>Buckbinder</surname><given-names>L.</given-names></name>; <name><surname>Carlo</surname><given-names>A. A.</given-names></name>; <name><surname>Conrad</surname><given-names>R.</given-names></name>; <name><surname>Cortes</surname><given-names>C.</given-names></name>; <name><surname>Dow</surname><given-names>R. L.</given-names></name>; <name><surname>Dowling</surname><given-names>M. S.</given-names></name>; <name><surname>El-Kattan</surname><given-names>A.</given-names></name>; et al. <article-title>Discovery of an in Vivo
Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment</article-title>. <source>ACS Med. Chem. Lett.</source>
<year>2015</year>, <volume>6</volume> (<issue>11</issue>), <fpage>1128</fpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.5b00215</pub-id>.<pub-id pub-id-type="pmid">26617966</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Fedorov</surname><given-names>O.</given-names></name>; <name><surname>Niesen</surname><given-names>F. H.</given-names></name>; <name><surname>Knapp</surname><given-names>S.</given-names></name>
<article-title>Kinase Inhibitor
Selectivity Profiling
Using Differential Scanning Fluorimetry</article-title>. <source>Methods
Mol. Biol.</source>
<year>2012</year>, <volume>795</volume>, <fpage>109</fpage><pub-id pub-id-type="doi">10.1007/978-1-61779-337-0_7</pub-id>.<pub-id pub-id-type="pmid">21960218</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Fedorov</surname><given-names>O.</given-names></name>; <name><surname>Marsden</surname><given-names>B.</given-names></name>; <name><surname>Pogacic</surname><given-names>V.</given-names></name>; <name><surname>Rellos</surname><given-names>P.</given-names></name>; <name><surname>Muller</surname><given-names>S.</given-names></name>; <name><surname>Bullock</surname><given-names>A. N.</given-names></name>; <name><surname>Schwaller</surname><given-names>J.</given-names></name>; <name><surname>Sundstrom</surname><given-names>M.</given-names></name>; <name><surname>Knapp</surname><given-names>S.</given-names></name>
<article-title>A Systematic Interaction Map of Validated
Kinase Inhibitors with
Ser/Thr Kinases</article-title>. <source>Proc. Natl. Acad. Sci. U. S.
A.</source>
<year>2007</year>, <volume>104</volume> (<issue>51</issue>), <fpage>20523</fpage><pub-id pub-id-type="doi">10.1073/pnas.0708800104</pub-id>.<pub-id pub-id-type="pmid">18077363</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Qiu</surname><given-names>J.</given-names></name>; <name><surname>Stevenson</surname><given-names>S. H.</given-names></name>; <name><surname>O&#x02019;Beirn</surname><given-names>M. J.</given-names></name>; <name><surname>Silverman</surname><given-names>R. B.</given-names></name>
<article-title>2,6-Difluorophenol
as a Bioisostere of a Carboxylic Acid: Bioisosteric Analogues of Gamma-Aminobutyric
Acid</article-title>. <source>J. Med. Chem.</source>
<year>1999</year>, <volume>42</volume> (<issue>2</issue>), <fpage>329</fpage><pub-id pub-id-type="doi">10.1021/jm980435l</pub-id>.<pub-id pub-id-type="pmid">9925739</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Jain</surname><given-names>R.</given-names></name>; <name><surname>Mathur</surname><given-names>M.</given-names></name>; <name><surname>Lan</surname><given-names>J.</given-names></name>; <name><surname>Costales</surname><given-names>A.</given-names></name>; <name><surname>Atallah</surname><given-names>G.</given-names></name>; <name><surname>Ramurthy</surname><given-names>S.</given-names></name>; <name><surname>Subramanian</surname><given-names>S.</given-names></name>; <name><surname>Setti</surname><given-names>L.</given-names></name>; <name><surname>Feucht</surname><given-names>P.</given-names></name>; <name><surname>Warne</surname><given-names>B.</given-names></name>; et al. <article-title>Discovery
of Potent and Selective RSK Inhibitors as
Biological Probes</article-title>. <source>J. Med. Chem.</source>
<year>2015</year>, <volume>58</volume> (<issue>17</issue>), <fpage>6766</fpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00450</pub-id>.<pub-id pub-id-type="pmid">26270416</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Barreiro</surname><given-names>E. J.</given-names></name>; <name><surname>Kummerle</surname><given-names>A. E.</given-names></name>; <name><surname>Fraga</surname><given-names>C. A. M.</given-names></name>
<article-title>The
Methylation Effect in Medicinal
Chemistry</article-title>. <source>Chem. Rev.</source>
<year>2011</year>, <volume>111</volume> (<issue>9</issue>), <fpage>5215</fpage><pub-id pub-id-type="doi">10.1021/cr200060g</pub-id>.<pub-id pub-id-type="pmid">21631125</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Leung</surname><given-names>C. S.</given-names></name>; <name><surname>Leung</surname><given-names>S. S. F.</given-names></name>; <name><surname>Tirado-Rives</surname><given-names>J.</given-names></name>; <name><surname>Jorgensen</surname><given-names>W. L.</given-names></name>
<article-title>Methyl
Effects on Protein-Ligand Binding</article-title>. <source>J. Med. Chem.</source>
<year>2012</year>, <volume>55</volume> (<issue>9</issue>), <fpage>4489</fpage><pub-id pub-id-type="doi">10.1021/jm3003697</pub-id>.<pub-id pub-id-type="pmid">22500930</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Xing</surname><given-names>L.</given-names></name>; <name><surname>Klug-Mcleod</surname><given-names>J.</given-names></name>; <name><surname>Rai</surname><given-names>B.</given-names></name>; <name><surname>Lunney</surname><given-names>E. A.</given-names></name>
<article-title>Kinase Hinge Binding
Scaffolds and Their Hydrogen Bond Patterns</article-title>. <source>Bioorg. Med. Chem.</source>
<year>2015</year>, <volume>23</volume> (<issue>19</issue>), <fpage>6520</fpage><pub-id pub-id-type="doi">10.1016/j.bmc.2015.08.006</pub-id>.<pub-id pub-id-type="pmid">26358279</pub-id></mixed-citation></ref></ref-list></back></article>